NCT05504837招募中1 期
KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 11
- 主要终点
- To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
研究概览
简要总结
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions
- •Subjects aged 18 years or older at the time of Informed Consent
- •A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:
- •A historical sweat chloride value >60 mmol/L
- •Two copies of a disease causing mutation in the CFTR gene
- •Clinically stable in the opinion of the Investigator
- •Percent predicted FEV1 ≥40% and ≤90% of the predicted normal for age, gender, and height at Screening
- •Resting oxygen saturation ≥92% on room air at Screening
排除标准
- •Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
- •Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
- •Treatment for Mycobacterium abscessus within 3 months prior to the first dose or more than two pulmonary exacerbations with a history of Burkholderia cenocepacia infection within 6 months prior to the first dose
- •Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
- •History of or listed for solid organ transplantation
- •Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
- •An active oral herpes infection 30 days prior to the first dose
- •Women who are pregnant or nursing
- •Subject who is unwilling to comply with contraception requirements per protocol
- •Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
- •Subject has a known hypersensitivity to inhaled glycerol
- •Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
- •Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator
- •Cohort 4 participants only: Subjects who are ineligible for, do not tolerate, or do not benefit from modulator therapy
研究组 & 干预措施
Cohort 3 (open label)
Experimental
Four administrations of KB407
干预措施: KB407 (Nebulization) (Biological)
Cohort 1 (open label)
Experimental
A single administration of KB407
干预措施: KB407 (Nebulization) (Biological)
Cohort 2 (open label)
Experimental
Two administrations of KB407
干预措施: KB407 (Nebulization) (Biological)
结局指标
主要结局
To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
时间窗: 2 months
Number of adult subjects with treatment related adverse events as assessed by NCI-CTCAE v5
次要结局
- To evaluate the effects of KB407 on pulmonary function, as measured by change from baseline in absolute and percent predicted FEV1(2 months)
研究者
研究点 (11)
Loading locations...
相似试验
招募中
1 期
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsLung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, AdultAdvanced CancerLung Cancer (NSCLC)NCT06228326Krystal Biotech, Inc.250
尚未招募
2 期
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsHemophilia a and BNCT06747416Suzhou Alphamab Co., Ltd.24
已完成
1 期
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPFIPFNCT06181370Agomab Spain S.L.143
已完成
1 期
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)Solid TumorsNCT00648648Merck Sharp & Dohme LLC206
已完成
1 期
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.Pulmonary Disease, Chronic ObstructiveNCT00453687GlaxoSmithKline12